Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of mecapegfilgrastim for prevention and treatment of antineoplastic therapy-associated neutropenia
ChiCTR1900021713Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in neutropenia, sponsored by Shandong Cancer Hospital. Primary endpoint: Routine blood test. Started Mar 2019; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on ChiCTR1900021713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021713.